Posted on Apr 29, 2021 8:21 AMUpdated Apr 29, 2021, 2:43 PM
Moderna does not intend to let her chance pass. After announcing at the beginning of the week an agreement with Sanofi for the shaping and bottling of 200 million doses at the American site of the French group in Ridgefield (New Jersey), the American biotech will make new investments in order to increase its global production capacities. Its ambition is to reach up to 3 billion doses in 2022, depending on the distribution of orders between the standard vaccine at 100 micrograms, and booster doses or for children at 50 micrograms, if they are properly authorized.
To do this, Moderna will double its RNA production and increase its bottling capacities outside the United States. And it will also increase its RNA production by 50% in the United States. Investments in the factories of the company and its subcontractors will begin in 2021 so that production is expected to reach 800 million to 1 billion doses by this year.